The study analyzed the evolution of white matter hyperintensities (WMH), lesions typically associated with cerebral vascular ...

The NHS spending watchdog must look again at its decision after drug manufacturers successfully appealed against Nice's ruling that the treatments were not cost-effective ...

Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed ...

Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are ...

What has long been interpreted as permanent and irreversible vascular damage may not be exclusively so. In people with Down syndrome—one of the most robust populations for studying Alzheimer's disease ...

People carrying at least one APOE4 allele have a higher risk of Alzheimer's disease compared with APOE3/3 carriers; people with two APOE4 alleles have the highest risk. The APOE2 allele is associated ...

New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked thanks to microscopic medicines developed by researchers at the University ...

Free educational event brings together clinical experts, resources, and community support for those navigating memory ...

Older people with a genetic risk of Alzheimer's disease did not experience the expected increase in cognitive decline and dementia risk if they consumed relatively large amounts of meat.

The groups are calling for genotype-informed prevention and treatment strategies, APOE stratification in clinical trials, and related public policies.

Black Americans are nearly twice as likely as their white counterparts to develop dementia, and researchers have found that obesity may be a significant factor in accelerating cognitive decline, ...